Abstract
Oxidatively modified low density lipoprotein (OxLDL), which is recognized by scavenger receptors, is now thought to be an important factor in atherogenesis. Since modifications occuring in OxLDL are complex and heterogenous, it is difficult to clarify the precise structures, metabolism, and localization of OxLDL in vivo. We have utilized a monoclonal antibody against OxLDL, which recognizes oxidized phosphatidylcholine (OxPC) molecules as its epitope, to study the feature of OxLDL present in vivo. So far we found from a number of co-laborating works that: (i) OxPC-apolipoprotein B complex occurs in OxLDL, (ii) OxLDL detected as LDL particles complexed with OxPC is present in human circulating plasma, (iii) the plasma OxLDL level is high in patients with certain diseases including heart diseases, (iv) OxPC-apolipoprotein B complex which corresponds to partially degraded OxLDL is present in atherosclerotic lesions in the human carotid artery and in foamy shaped macrophages in culture, and finally (v) OxPC is likely to be involved in macrophage recognition of OxLDL particles. Recently several studies showed OxPC can stimulate vessel wall cells including endothelial cells and macrophages. OxPC is thought to be an important molecule as a marker for OxLDL in vivo, as well as a pathological ustimulant involved in atherogenesis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
